EGFR and cancer: An organoid model (Fig. 3) was established by culturing the patient's cancer tissue from surgical resection and used for drug screening as described by Sachs.[6] The DNA sequencing result revealed an identical EGFR double mutation 19Del (p.L747_S752delinsQH)/L643V was detected in corresponding cancer organoids (Fig. 2a).